Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Safety Risks for Dexamethasone, Teicoplanin
March 28, 2022
- MHLW Study Group Proposes Using Private Data to Monitor Vaccine Distribution and Shortages
March 28, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
March 25, 2022
- Precedex Gets 1st Designation as Drug for Specific Use
March 25, 2022
- MHLW Study Group Kicks Off Discussions on Use of Pseudonymously Processed Information
March 25, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
- CEFP Calls for Planned Healthcare Investments over Years
March 24, 2022
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
- PMDA to Publish Examples of Shortfalls Found in GMP Inspections
March 24, 2022
- Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
March 24, 2022
- Alexion’s Bleeding Antidote to Be Approved as Early as This Month
March 24, 2022
- Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
March 24, 2022
- Ensure Appropriate Care System for Post-COVID Vaccination Symptoms: MHLW Panels
March 23, 2022
- PMDA to Launch “GMP Roundtable” with Academia, Industry
March 23, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- MHLW to Order Label Revision for Somatropin, IFNβ-1a/1b Preparations
March 23, 2022
- Safety Panel OKs FY2022 Survey on US, EU Quality Control Systems, Questions Lagevrio Measures
March 22, 2022
- Conduct Yearly Surprise GMP Inspections for High-Risk Sites: MHLW
March 22, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…